HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
TACE plus immunotherapy outcomes in intermediate and advanced hepatocellular carcinoma patients
New risk markers found for liver cancer patients getting combined therapy
This cohort study of 243 patients with intermediate and advanced hepatocellular carcinoma identified independent risk factors for tumor prog…
Doctors identified key blood and scan markers that predict how liver cancer progresses in patients receiving a specific combined treatment p…
Narrative review offers theoretical guidance for early prevention, treatment, and prognosis of hepatocellular carcinoma
New Framework Reveals How Inflammation Fuels Liver Cancer
This narrative review provides systematic theoretical guidance for early prevention, precise treatment, and prognosis improvement of hepatoc…
Understanding inflammation helps doctors stop liver cancer before it spreads.
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
Expert consensus guideline on TACE for unresectable HCC in Vietnam
Vietnam Unveils New Rules for Liver Cancer Treatment
This expert consensus guideline addresses transarterial chemoembolization (TACE) for patients with unresectable hepatocellular carcinoma in …
Vietnam’s medical leaders have created a clear plan to improve liver cancer care.
Integrative review of Epimedium flavonoids in hepatitis and cirrhosis shows preclinical promise but lacks clinical validation
Ancient Herb Shows New Promise for Liver Scarring and Hepatitis
This integrative review synthesizes data from 33 high-impact studies regarding Epimedium species and its bioactive flavonoids, icariin and i…
This research suggests a traditional herb may offer a new way to protect the liver, but more work is needed to prove it’s safe and effective…
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma
New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma.
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Huaier granules combined with conventional therapy may improve survival in hepatocellular carcinoma
Does adding Huaier granules help liver cancer patients live longer when combined with standard treatment?
This systematic review of 4,832 patients found that Huaier granules combined with conventional cancer therapy was associated with improved o…
Adding Huaier granules to standard liver cancer treatment helped patients live longer and slowed disease growth compared to therapy alone.
Meta-analysis links rare APOB variants to advanced MASLD, cirrhosis, and hepatocellular carcinoma across large cohorts
Do rare gene changes linked to liver disease also raise your risk for cancer and scarring?
This meta-analysis reviews data from the Million Veteran Program, UK Biobank, and clinical cohorts to assess rare APOB variant carriage in p…
Rare gene changes linked to fatty liver disease also raise your risk for liver cancer and severe scarring, according to new findings.
Systematic review examines immunotherapy resistance mechanisms and strategies in hepatocellular carcinoma patients
Why Liver Cancer Stops Responding to Immunotherapy — and What Could Change That
This systematic review evaluated drug resistance mechanisms and strategies to overcome resistance in patients with hepatocellular carcinoma …
Understanding why liver cancer learns to dodge the immune system's attack is the first step toward treatments that can keep working long-ter…
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies
Review suggests metabolic switch concept may guide future liver cancer treatments
This mini-review examines the role of ACSL4 as a metabolic switch rather than a static oncogenic factor in hepatocellular carcinoma.
Viewing a liver cancer protein as a metabolic switch could guide new therapies that boost a specific cell death process to fight tumors.
Review of bile acid homeostasis regulation in liver disease and cancer
Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…